NCT01992042View on ClinicalTrials.gov

Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

December 31, 2016

Conditions
Prostate Cancer
Interventions
DRUG

Fluvastatin

HMG-CoA reductase inhibitors that lowers cholesterol levels. 40mg twice daily

DRUG

Pimonidazole

Trial Locations (1)

M5G2M9

University Health Network- The Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT01992042 - Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer | Biotech Hunter | Biotech Hunter